| 1 |
32320483 | Clinically Relevant Cytochrome P450 3A4 Induction Mechanisms and Drug Screening in Three-Dimensional Spheroid Cultures of Primary Human Hepatocytes. | 2020 Oct |
1 |
| 2 |
31187169 | The effects of lapatinib on cardiac repolarization: results from a placebo controlled, single sequence, crossover study in patients with advanced solid tumors. | 2019 Aug |
1 |
| 3 |
31312984 | Theoretical study on the mechanism of N- and α-carbon oxidation of lapatinib catalyzed by cytochrome P450 monooxygenase. | 2019 Jul 16 |
1 |
| 4 |
31372791 | Risk factors associated with the incidence and time to onset of lapatinib-induced hepatotoxicity. | 2019 Nov |
1 |
| 5 |
31492693 | Interindividual Variation in CYP3A Activity Influences Lapatinib Bioactivation. | 2019 Nov |
10 |
| 6 |
27942916 | Synergistic disruption of ERα/HER2 crosstalk by endoxifen and lapatinib in breast cancer cells. | 2017 Jan |
1 |
| 7 |
29098381 | The effects of lapatinib on CYP3A metabolism of midazolam in patients with advanced cancer. | 2017 Dec |
4 |
| 8 |
27450182 | Cytochrome P450 3A4 and CYP3A5-Catalyzed Bioactivation of Lapatinib. | 2016 Oct |
13 |
| 9 |
25639891 | Mechanism-based inactivation of CYP450 enzymes: a case study of lapatinib. | 2015 Feb |
1 |
| 10 |
24191259 | Studies on the role of metabolic activation in tyrosine kinase inhibitor-dependent hepatotoxicity: induction of CYP3A4 enhances the cytotoxicity of lapatinib in HepaRG cells. | 2014 Jan |
9 |
| 11 |
24800949 | Phase I study of weekly paclitaxel in combination with pazopanib and lapatinib in advanced solid malignancies. | 2014 May 27 |
1 |
| 12 |
23404373 | Metabolism-dependent inhibition of CYP3A4 by lapatinib: evidence for formation of a metabolic intermediate complex with a nitroso/oxime metabolite formed via a nitrone intermediate. | 2013 May |
4 |
| 13 |
23928571 | Coadministration of lapatinib increases exposure to docetaxel but not doxorubicin in the small intestine of mice. | 2013 Oct |
1 |
| 14 |
22370628 | Effect of CYP3A4 inducer dexamethasone on hepatotoxicity of lapatinib: clinical and in vitro evidence. | 2012 Jun |
2 |
| 15 |
22511346 | Interaction of lapatinib with cytochrome P450 3A5. | 2012 Jul |
2 |
| 16 |
21363997 | Metabolic intermediate complex formation of human cytochrome P450 3A4 by lapatinib. | 2011 Jun |
1 |
| 17 |
21553932 | Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on 4-anilinoquinazolines. | 2011 Jun |
1 |
| 18 |
20624855 | Mechanism-based inactivation of cytochrome P450 3A4 by lapatinib. | 2010 Oct |
5 |
| 19 |
19371315 | Effects of ketoconazole and carbamazepine on lapatinib pharmacokinetics in healthy subjects. | 2009 Apr |
2 |
| 20 |
18803986 | Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases. | 2008 Aug |
1 |
| 21 |
18472989 | A review of lapatinib ditosylate in the treatment of refractory or advanced breast cancer. | 2007 Aug |
1 |